EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The genomic puzzle of Rosai-Dorfman disease

Sarah Binhassan

Frontiers in Oncology · 16.11.2026 · 16

DOI: 10.3389/fonc.2026.2016300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 16.11.2026. Verfasst von Sarah Binhassan. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rosai-Dorfman disease (RDD) was long regarded as a reactive histiocytic proliferation, consistent with its frequent spontaneous regression and the absence of identified clonal drivers. This view began to shift in 2016–2017, when recurrent activating mutations in KRAS and MAP2K1 were identified in a subset of cases, prompting partial reclassification of RDD as a clonal neoplasm. This review synthesises the genetic and genomic testing literature in RDD published 2014–2025, drawing on nineteen cohort studies and conference abstracts identified through a structured PubMed search and citation chaining. Reported mutation-positive rates range from 0% to approximately 83% depending on cohort, sequencing method, and anatomic site, with KRAS and MAP2K1 the most frequently implicated genes. Cutaneous disease shows a distinct NRAS -dominant profile, while intraosseous disease trends toward mutation negativity, though each rests upon a few cohorts. Beyond MAPK, recurrent findings in CSF1R and other receptor tyrosine kinases, alongside a scattered catalog of epigenetic and myeloid-malignancy-associated alterations, indicate that the genomic landscape extends beyond one pathway. Population data remain sparse: Saudi and Japanese cohorts diverge from the North American and Chinese literature dominating this field, but neither is large enough to establish a stable population-level profile. Small samples, heterogeneous platforms, inconsistent testing completeness, and few prospective multi-center cohorts limit how confidently mutation rates can be generalised. This review discusses the competing reactive and neoplastic interpretations of RDD, the concepts needed to interpret its genomic data, and emerging diagnostic and genotype-informed therapeutic developments. RDD is best understood as a genomically defined clonal subset within a broader, poorly characterised population, not a disease fully reclassified from reactive to neoplastic. Prospective, uniformly sequenced, multi-institutional studies including underrepresented populations are needed to resolve this picture.

Zitieren

APA

Binhassan, S. (2026). The genomic puzzle of Rosai-Dorfman disease. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.2016300

Vancouver

Binhassan S. The genomic puzzle of Rosai-Dorfman disease. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.2016300

BibTeX
@article{Binhassan2026,
  author = {Binhassan, Sarah},
  title = {The genomic puzzle of Rosai-Dorfman disease},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.2016300}
}
Kostenlos starten →